Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InhaleRx Limited ( (AU:NX1) ) has issued an announcement.
Nexalis Therapeutics has issued a proxy voting form ahead of its annual general meeting scheduled for 29 May 2026, which will be held virtually, outlining how shareholders can appoint proxies and cast votes electronically or by traditional channels. The agenda includes adoption of the remuneration report, potential spill resolution, re-election of director Dr. Ron Wise, approval of an additional placement capacity, issuance of share rights to directors in lieu of fees, and ratification of prior share and placement issues, signalling ongoing efforts to manage board composition, capital structure and director remuneration.
The chair intends to vote undirected proxies in favour of all resolutions except the proposed spill resolution, and shareholders are specifically asked to authorise the chair to vote on remuneration-related items even where they involve key management personnel. These governance proposals and capital-ratification measures may influence Nexalis Therapeutics’ funding flexibility, board stability and alignment of director incentives with shareholders, making the meeting a key event for investors monitoring the company’s strategic and financial direction.
More about InhaleRx Limited
Nexalis Therapeutics Ltd operates in the biotechnology and therapeutics sector, focusing on drug development and related medical innovations. The company is publicly listed and governed by a board of directors whose remuneration and equity-based compensation are subject to shareholder approval at annual general meetings.
Average Trading Volume: 164,123
Technical Sentiment Signal: Sell
Current Market Cap: A$5.82M
For detailed information about NX1 stock, go to TipRanks’ Stock Analysis page.